Pimozidum [INN-Latin]

• Anti-Dyskinesia Agents
• Antipsychotic Agents
• Dopamine Antagonists
• ATC:N05AG02

• Haldol decanoate
• Halomonth
• Neoperidole
• Opiran
• Orap
• Pimozide [USAN:BAN:INN:JAN]
• Pimozidum [INN-Latin]
• Primozida [INN-Spanish]

• No information avaliable

C₂₈H₂₉F₂N₃O

http://www.rxlist.com/cgi/generic3/orap.htm

Pimozidum_[INN-Latin] MSDS

No information avaliable

461.546 g/mol

214-218 ^oC

10 mg/L

Solid

5.761

Tablet

Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.

Pimozide is an orally active antipsychotic drug product which shares with other antipsychotics the ability to blockade dopaminergic receptors on neurons in the central nervous system. However, receptor blockade is often accompanied by a series of secondary alterations in central dopamine metabolism and function which may contribute to both pimozide's therapeutic and untoward effects. In addition, pimozide, in common with other antipsychotic drugs, has various effects on other central nervous system receptor systems which are not fully characterized. Pimozide also has less potential for inducing sedation and hypotension as it has more specific dopamine receptor blocking activity than other neuroleptic agents (and is therefore a suitable alternative to haloperidol).

Greater than 50% absorption after oral administration. Serum peak appears 6-8 hours post ingestion.

LD₅₀ = 1100 mg/kg (rat, oral), 228 mg/kg (mouse, oral)

No information avaliable

Humans and other mammals